Clinical trial
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
NCT00003726 · Dartmouth-Hitchcock Medical Center, Other · Terminated
Key facts
| NCT number | NCT00003726 |
|---|---|
| Title | Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer |
| Official title | A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological |
| Interventions | lepirudin |
| Enrollment | 1 |
| Start date | Nov 1, 1998 |
| Primary completion | Jul 1, 2001 |
| Completion | Jul 1, 2001 |
| First posted | May 3, 2004 |
| Last update posted | Aug 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: